When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SGIOY - ViiV Healthcare reports positive data on less-frequent dosing of HIV regimen
Shionogi & Co. Ltd. ADR
Results from a Phase 3 clinical trial, ATLAS-2M, evaluating the combination of ViiV Healthcare's cabotegravir and Johnson & Johnson's (JNJ-2.7%) rilpivirine for the treatment of HIV infection showed the non-inferiority (no worse than) of a two-month dosing interval compared to a month interval. The data were presented at the Conference on Retroviruses and Opportunistic Infections in Boston.
More news on: Johnson & Johnson, GlaxoSmithKline plc, Pfizer Inc., Healthcare stocks news,